Nasdaq · Biotech stocks database
EPRX (Eupraxia Pharmaceuticals Inc.) stock: $8.58, $565.5M market cap, $80.6M cash, $484.9M EV, $650.2M fully diluted market cap. Next expected readout: Dec-26. Lead program: EP-104GI (Eosinophilic Esophagitis), Phase 2. Data from Fully Diluted's biotech stocks database.
| Cash | $80.6M |
|---|---|
| Debt | $0.0M |
| Net cash | $80.6M |
| Enterprise value | $484.9M |
| Basic shares | 65.9M shares |
| Fully diluted shares | 75.8M shares |
| Fully diluted market cap | $650.2M |
| Cash per share | $1.22 |
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Loading EPRX daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Jan 12 - Feb 23 | EP-104GI | Phase 2 | Eosinophilic Esophagitis | Q4 2026 |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.